W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 523: Protect Medical Innovation Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Promoted life sciences community and communicated economic and health benefits of the industry. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. S. 957: Drug Supply Chain Security Act. S. 959: Pharmaceutical Compounding Quality and Accountability Act.H.R. 3089: Compounding Clarity Act of 2013. H.R. 3024: The Drug Quality and Security Act. H.R. 2725: Food and Drug Administration Safety Over Sequestration Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Medicare/Medicaid MMM
Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.